Byoungseo Choi on Celltrion's Biosimilar Goals For 2030
Season 3, Episode 14, Jul 19, 2020, 11:00 AM
With its infliximab biosimilar, CT-P13 (Inflectra, Remsima) is undergoing trials as a possible treatment for coronavirus disease 2019 (COVID-19), Celltrion Healthcare also has ambitious plans to launch 1 new biosimilar per year through 2030.
We sat down with Byoungseo Choi, the head of marketing for Celltrion Healthcare, to discuss exactly how this plan is going to work, the company’s current biosimilar pipeline, and its expectations for how their products will perform.
To learn more about Celltrion Healthcare, visit celltrionhealthcare.com.
You can learn more about the testing of Celltrion's infliximab biosimilar for the treatment of COVID-19 here.
You can learn more about the testing of Celltrion's infliximab biosimilar for the treatment of COVID-19 here.